clinical trial · NCT04752774
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
Ipsen·phase2·recruiting·n = 240
SpasticityIPN10200PlaceboDysport
brief summary
The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
started
Apr 29, 2021
primary completion
Oct 30, 2027
completion
Oct 30, 2027
last updated
Apr 6, 2026
official title
An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol